Semaglutide's cardiovascular benefits are consistent across different baseline HbA1c levels in people with overweight or obesity and atherosclerotic cardiovascular disease
Current assessment
Synthesis pending
Confidence
Not assessed
Supporting evidence (0)
Nothing recorded on this side
Contradicting evidence (0)
Nothing recorded on this side
Discussion (0)
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.